Diversified Partnerships And Digital Transformation Will Drive Future Potential

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

29 Mar 25

Updated

16 Dec 25

Views

32

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-46.0%

7D

2.0%

Loading

1Y

-46.0%

7D

2.0%

You can edit this narrative until Dec 17 11:05 AM. Then, changes will post as Updates.

Author's Valuation

US$7.3372.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 16 Dec 25

OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside

Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.

Shared on 02 Dec 25

OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead

OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.

Shared on 18 Nov 25

Fair value Decreased 6.67%

OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside

Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.

Shared on 01 May 25

Fair value Decreased 0.79%

Shared on 24 Apr 25

Fair value Decreased 7.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.64%

AnalystConsensusTarget has decreased revenue growth from 29.5% to 26.1% and increased future PE multiple from 170.5x to 205.8x.

AnalystConsensusTarget Fair Value

US$7.33

72.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

31.77%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.88%

Calculation

US$11.47m

Earnings '28

x

189.19x

PE Ratio '28

=

US$2.17b

Market Cap '28

US$2.17b

Market Cap '28

/

235.72m

No. shares '28

=

US$9.21

Share Price '28

US$9.21 Share Price '28

Discounted to 2025 @ 7.88% p.a.

=

US$7.33

Fair Value '25